Applications of (S)-3-Amino-3-(3-Bromo-Phenyl)-Propionic Acid in Industrial Manufacturing

(S)-3-Amino-3-(3-Bromo-Phenyl)-Propionic Acid is a highly specialized chiral intermediate utilized throughout the pharmaceutical and fine chemical industries. As the direct manufacturer, we focus on its use in strictly verified sectors, supplying to downstream partners who demand precision in their synthesis and regulatory adherence in their processes. Below are primary application sectors where this compound serves as an essential raw material integrated into specific manufacturing stages and final end-product portfolios.

1. Chiral Pharmaceutical Intermediates for CNS Active Compounds

Our material functions as a chirality source for the synthesis of active pharmaceutical ingredients (APIs) in the central nervous system (CNS) drug field. It enters the process at an early intermediate stage, supporting asymmetric synthesis routes for anticonvulsants and neuroprotective agents. Downstream partners rely on its stereochemical purity to ensure batch-to-batch consistency and to meet advanced pharmacopoeia standards during final API crystallization.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice (GMP) for APIs
• EU GMP Part II for API Synthesis and Control
• USP and EP monograph requirements (residual solvents, chiral identity)
• FDA 21 CFR Part 211 (where relevant to API manufacturing)

Typical usage ratio

• 0.95 – 1.06 molar equivalent as core intermediate (adjusted based on target molecule and synthesis route selection)

Downstream process integration

• Introduced during the asymmetric step in the main reaction phase, commonly via amide coupling or esterification; downstream conversion through reduction, hydrolysis, or protection group manipulation before API finalization.

Final product types

• Chiral APIs for anticonvulsants (e.g., Brivaracetam, analogues)
• Intermediates for GABAergic modulating drugs
• CNS-targeted research compounds

2. Synthesis of Peptidomimetic Drug Candidates

Structural features of the compound allow for its use as a building block in the scalable synthesis of peptidomimetic frameworks. Its incorporation supports development projects and cGMP pathway manufacturing for drug research organizations, especially where brominated aromatic rings are essential for molecular binding or target selectivity.

Industry compliance standards

• ISO 9001:2015 Quality Management System
• FDA Guidance for Industry: Q11 (Development and Manufacture of Drug Substances)
• ICH Q11 for complex peptide and peptidomimetic synthesis

Typical usage ratio

• 0.5–2.0 equivalent per peptide coupling cycle, depending on length and substitution required for the peptidomimetic scaffold

Downstream process integration

• Introduced following Fmoc/Boc-protected solid-phase or solution-phase synthesis; participates in amide bond formation with specific protected amino acids or functional linkers.

Final product types

• Peptidomimetic lead compounds for preclinical evaluation
• Brominated peptide analogues for biochemical screening
• Custom oligopeptide fragments for structure-activity relationship (SAR) studies

3. Specialty Fine Chemical Building Blocks

Manufacturers in the fine and specialty chemicals industry incorporate this compound as a functionalized aromatic amino acid derivative, supporting advanced molecule construction in crop protection and analytical reagent synthesis. The bromo-phenyl propionic acid motif is regularly chosen to introduce a precise electronic or steric influence during target molecule design in non-pharmaceutical sectors.

Industry compliance standards

• REACH Registration (EC 1907/2006)
• ISO 9001/14001 Environmental & Quality Systems
• Specific customer or downstream synthetic audit protocols

Typical usage ratio

• 1.0 equivalent as coupling or alkylation agent; ranges up to 3.0 equivalent in multi-functional assembly or conjugation

Downstream process integration

• Integrated as a starting material for halogenated intermediates; undergoes direct derivatization, cross-coupling, or chain extension reactions in batch or continuous reactor systems.

Final product types

• Analytical reference standards
• Non-agrochemical brominated fine chemicals for research
• Precursor substances for crop protection R&D

4. Preparation of Radiolabeling Precursors for Diagnostic Agents

The bromo functionality of this compound enables its use in halogen exchange protocols for the synthesis of radioisotope-labeled precursors, facilitating the manufacture of PET and SPECT tracer candidates. Radiochemical manufacturers depend on the high purity grade to minimize undesired isotopic dilution and ensure compliance throughout isotope incorporation and downstream purification.

Industry compliance standards

• cGMP for Radiopharmaceutical Manufacturing (US Pharmacopeia Chapter <823>)
• European Pharmacopoeia monographs for PET/SPECT tracers
• ISO 13485 for Medical Device Quality Management (applicable for diagnostic kit use)

Typical usage ratio

• 1.0 equivalent as substrate for nucleophilic substitution; adjusted from 0.8 to 1.2 equivalent depending on isotopic exchange efficiency

Downstream process integration

• First introduced in the halogen exchange or nucleophilic aromatic substitution stage, supporting direct incorporation of 18F, 123I, or 77Br, followed by rapid isolation and QC of labeled intermediate prior to formulation.

Final product types

• PET tracer precursor molecules
• Radiolabeled diagnostic agent substrates
• Quality control standards for nuclear medicine laboratories

5. Development of Advanced Organic Electronic Materials

Some R&D and pilot-scale manufacturers in the organic electronics sector utilize this compound to modify electronic and steric parameters in the boundary region of dopant, charge transport, or optoelectronic device synthesis. Its precise amino and bromo-phenyl substitution pattern facilitates the molecular engineering required for organic semiconductors and advanced functional interface materials.

Industry compliance standards

• ISO 9001:2015 Quality Management
• RoHS Directive 2011/65/EU (where applicable for electronic substances)
• IEC 62474 Material Declaration Standard (for supply chain transparency)

Typical usage ratio

• 0.1 – 0.5 wt% as functionalized dopant or additive; higher loadings tested during screening for new material systems

Downstream process integration

• Employed in solution or melt-phase as precursor for subsequent coupling, polymerization, or surface treatment; participates in device fabrication trial runs or as test substrate in small-batch pilot studies.

Final product types

• Small-molecule hole transport materials for OLEDs or OPVs
• Brominated aromatic additives for semiconductor doping
• Prototype electronic devices for academic-industry commercialization programs